Oncology Consortium

Impactful Education Through Innovative Engagement

roy.berger@theoncologyconsortium.com | (516) 729-0303

E. Roy Berger, MD, FACP

Urologic Oncology Consortium

Assistant Clinical Professor of Medicine, SUNY Stony Brook College of Medicine Stony Brook, NY. Medical Oncologist with over 30 years of experience in the diagnosis and treatment of solid tumors, hematologic malignancies and supportive care. Founding member of the Prostate Cancer Education Council, a group that sponsors free prostate cancer screenings nationally. In addition, he serves on the medical advisory boards of two of the largest patient advocacy groups in the US for patients with prostate cancer. Authored over 50 peer reviewed articles and participated in 100 clinical trials.

Ronald Bukowski, MD

Dermatologic and Urologic Oncology Consortium

Emeritus staff at the Cleveland Clinic Foundation, and Professor of Medicine, Cleveland Clinic Lerner College of Medicine, Case Western Reserve University. He was recently the Deputy Director of the Cleveland Clinic Taussig Cancer Center and Director of the Experimental Therapeutics at the Cleveland Clinic Cancer Center. He held the James Zito Chair in Cancer Research at the Taussig Cancer Center from 2001 to 2008.

Sia Daneshmand, MD

Urologic Oncology Consortium

Dr. Sia Daneshmand has been selected as one of “True Experts” in the Testicular Cancer Resource Center web site, and serves on the scientific advisory board of the bladder cancer advocacy network (BCAN). He has been elected to the Alpha Omega Alpha medical honor society, and has been designated one of the “America’s Top Cancer Doctors” and “America’s Top Urologists” and “America’s Top Doctors” for the past 6 years. He is an active member of the Society of Urologic Oncology, has presented over 200 abstracts at scientific meetings and authored over 180 peer-reviewed articles, reviews, and chapters.

Stephen Freedland, MD

Urologic Oncology Consortium

Dr. Stephen Freedland is a Professor of Surgery (Urology) at Cedars-Sinai Medical Center in Los Angeles, CA. He is Associate Director of the Samuel Oschin Comprehensive Cancer Institute and Director of the Center for Integrated Research on Cancer and Lifestyle. Until the end of 2014, he was an Associate Professor of Surgery (Urology) and Pathology at Duke University. He is Editor-in-Chief of Prostate Cancer and Prostatic Diseases and sits on the editorial board of numerous international journals in Urology and Cancer. He specializes in the diagnosis, treatment, and long-term management of prostate cancer patients. He has extensive research interests in risk stratification, the role of obesity and nutrition in prostate cancer, and health disparities for prostate cancer. He completed his undergraduate at UCLA and then medical school at UC Davis. Following this, he completed his residency in Urology at UCLA and a urological oncology fellowship at Johns Hopkins. He currently runs an active research program with funding from the National Cancer Institute and the Department of Defense.

Thomas E. Hutson, DO

Urologic Oncology Consortium

Director of the Genitourinary Oncology Program and Co-Director of the Center of Excellence for Texas Oncology in the Charles A. Sammons Cancer Center at Baylor University Medical Center; and Co-Chair of Genitourinary Research for US Oncology. Professor of Medicine at Texas A&M Health Science Center College of Medicine.

Primo Lara, MD

Thoracic and Urologic Oncology Consortium

Dr. Lara is Professor of Medicine at the University of California Davis School of Medicine. He is also Associate Director for Translational Research and Co-Leader of the Cancer Therapeutics Program at the UC Davis Comprehensive Cancer Center, a National Cancer Institute-designated cancer center. His principal research interest is in the field of developmental therapeutics, particularly in thoracic and genitourinary malignancies.

Robert Motzer, MD

Urologic Oncology Consortium

Dr. Motzer serves as Attending Physician, Division of Solid Tumor Oncology, Department of Medicine, Memorial Hospital for Cancer and Allied Disease as well as Attending Physician and Professor of Medicine, Weill Medical College of Cornell University and New York Presbyterian Hospital.

Brian I. Rini, MD, FACP

Urologic Oncology Consortium

Brian I. Rini, MD, FACP is a Professor of Medicine at the Cleveland Clinic Lerner College of Medicine of Case Western Reserve University in Cleveland, Ohio. A Staff member of the Department of Solid Tumor Oncology and Co-Leader of the Genitourinary Program of the CASE Comprehensive Cancer Center, Dr. Rini’s work focuses on genitourinary malignancies. Dr. Rini earned his medical degree at the Ohio State University College of Medicine. He completed a Residency program in Internal Medicine and a Fellowship in Hematology / Oncology at University of Chicago Hospitals. Dr. Rini was an Assistant Professor at the University of California San Francisco before moving to The Cleveland Clinic.

Charles J. Ryan, MD

Urologic Oncology Consortium

Charles J Ryan, MD, is a Professor of Medicine and Urology at the Helen Diller Family Comprehensive Cancer Center at the University of California, San Francisco (UCSF). He is the Leader of the Genitourinary Medical Oncology Program, overseeing the clinical research efforts of a group of nine genitourinary medical oncologists conducting clinical trials in prostate, kidney and bladder cancer.

Mark C. Scholz, MD

Urologic Oncology Consortium

A board-certified medical oncologist, Mark C. Scholz, MD, serves as medical director of Prostate Oncology Specialists Inc. in Marina del Rey, CA, a medical practice exclusively focused on prostate cancer. He is also the executive director of the Prostate Cancer Research Institute. He received his medical degree from Creighton University in Omaha, NE, Dr. Scholz completed his Internal Medicine internship and Medical Oncology fellowship at University of Southern California Medical Center.

Cora N. Sternberg, MD, FACP

Urologic Oncology Consortium

Dr. Sternberg was the Coordinator for Genitourinary Oncology Education for the European Society for Medical Oncology (ESMO) for many years and has also served on the nominating Committee. She has served as the Genitourinary Oncology Program Chairman for the European CanCer Organisation (ECCO) and coordinated the first European Multidisciplinary Genitourinary Cancer Symposium (EMUC).

Winston W. Tan, MD

Supportive Care and Urologic Oncology Consortium

Dr. Winston Tan has been engaged in research with a focus on genitourinary cancer, including prostate cancer, since 1997. His research has focused on two distinct areas: developing novel therapeutic agents for patients with genitourinary cancer, and developing interventions/ recognizing quality of life issues in patients with genitourinary cancer. He specifically is interested and has published on issues regarding bone health. He has written and completed several investigator-initiated Phase II clinical trials, served as a principal investigator on multiple trials, and additionally has served as a principal investigator for a Phase III clinical trial. He has authored 31 peer reviewed articles, seven book chapters and 45 abstracts.in addition,Dr. Tan actively runs the medical oncology clinic for kidney cancer at the Mayo Clinic in Jacksonville, Florida. He is an active member of Genitourinary Committee with the Eastern Cooperative Oncology Group.

Nicholas Vogelzang, MD

Urologic Oncology Consortium

Dr. Vogelzang is Clinical Professor of Medicine at the University of Nevada School of Medicine, and a Medical Oncologist at the Comprehensive Cancer Centers of Nevada (CCCN) in Las Vegas. He is Associate Chair of the Genitourinary (GU) Committee, and Associate Editor of the Kidney Cancer Journal and Clinical Genitourinary Cancer.

Download Capability Slide

Oncology Consortium | All Rights Reserved 2012-2017
Back to Top